VEGFA and cancer: Specifically, in 2018, the FDA approved bevacizumab, an anti‐VEGF immunotherapy, as a combination therapy with carboplatin and paclitaxel,104, 105 and in 2020, olaparib, a PARP inhibitor, was approved in combination with bevacizumab for patients with homologous recombination‐deficient cancers.106, 107